Parkinson’s Disease

Glutathione, oxidative stress and neurodegeneration
Schulz JB, Lindenau J, Seyfried J, Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem. 2000 Aug;267(16):4904-11. PMID: 10931172

Oxidative stress as a cause of nigral cell death in Parkinson’s disease and incidental Lewy body disease
Jenner P, Dexter DT, Sian J, Schapira AH, Marsden CD. Oxidative stress as a cause of nigral cell death in Parkinson’s disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson’s Disease Research Group. Ann Neurol. 1992;32 Suppl:S82-7. PMID: 1510385

Parkinson’s disease as multifactorial oxidative neurodegeneration: implications for integrative management
Kidd PM. Parkinson’s disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern Med Rev. 2000 Dec;5(6):502-29. PMID: 11134975

Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration
Chinta SJ, Kumar MJ, Hsu M, Rajagopalan S, Kaur D, Rane A, Nicholls DG, Choi J, Andersen JK. Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. J Neurosci. 2007 Dec 19;27(51):13997-4006. PMID: 18094238

Glutathione in Parkinson’s disease: a link between oxidative stress and mitochondrial damage?
Di Monte DA, Chan P, Sandy MS. Glutathione in Parkinson’s disease: a link between oxidative stress and mitochondrial damage? Ann Neurol. 1992;32 Suppl:S111-5. PMID: 1510368

Reduced intravenous glutathione in the treatment of early Parkinson’s disease
Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM, Rosati G. Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 1996 Oct;20(7):1159-70.PMID: 8938817